|
Drug giant Glaxo SmithKline (GSK) has decided to conduct simultaneous trials of new molecules in all major parts segments of India. MNC Pharma firms were not allowed to to conduct clinical trials of new molecules in India till the government amended schedule. GSK India managing director Kalayanasundaram said "We will conduct simultaneous clinical trials in major therapeutic areas like oncology, anti-cholestrol and diabetics along with all other centres across the globe." GSKs new collaboration with the University of Oxford is expected to enable the evaluation of new treatments in a range of cancer types more prevalent in India like the cancers of gallbladder, liver and cervix, GSKs M.D said. MNC drug firms have been conducting Phase1 trials ,and Phase2 trials in India for the past few years. However, the trials were restricted to molecules which had already been tried in other countries. GSK is working on its oncology research molecule Lapatinib, a dual action treatment ,being developed initially for breast cancer. Other MNCs lke Pfizer ,Eli Lilly, GSK, Sanofi-Aventisand Roche have already started piece-meal phase 1and 2 trials in India. World-wide ,the average cost of developing one molecule is about $282m and takes about seven years. Statistics underline the growing clinical trials market in India. Mc Kinsey estimates say that by 10,global pharma majors will spend up to %1.5bn on drug trials in India .This is roughly 20% of Indias estimated total pharma exports by 10.
|
|
|
|
|
| Posted : 11/22/2005 |
|
|
|
|
